Citius Oncology, Inc. (CTOR)

Citius Oncology Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022
Cash & Equivalents	3.92	0	-	-
Cash & Short-Term Investments	3.92	0	-	-
Cash Growth	3504282.14%	-	-	-
Inventory	22.29	8.27	-	-
Prepaid Expenses	1.33	2.7	7.73	2.69
Total Current Assets	27.54	10.97	7.73	2.69
Long-Term Deferred Charges	73.4	73.4	40	40
Total Assets	100.94	84.37	47.73	42.69
Accounts Payable	13.23	3.71	1.29	0.09
Accrued Expenses	13.61	0.59	19.76	5.75
Other Current Liabilities	22.65	28.4	-	-
Total Current Liabilities	49.49	32.7	21.05	5.85
Long-Term Debt	3.8	3.8	-	-
Long-Term Deferred Tax Liabilities	2.78	1.73	1.15	0.58
Other Long-Term Liabilities	-	-0	-	-
Total Liabilities	56.08	38.23	22.2	6.42
Common Stock	0.01	0.01	0.01	0.01
Additional Paid-In Capital	108.9	85.41	43.66	41.69
Retained Earnings	-64.04	-39.28	-18.13	-5.43
Shareholders' Equity	44.87	46.14	25.54	36.27
Total Liabilities & Equity	100.94	84.37	47.73	42.69
Total Debt	3.8	3.8	-	-
Net Cash (Debt)	0.12	-3.8	-	-
Net Cash Per Share	0.00	-0.06	-	-
Filing Date Shares Outstanding	84.8	71.55	67.5	67.5
Total Common Shares Outstanding	83.51	71.55	67.5	67.5
Working Capital	-21.95	-21.73	-13.31	-3.16
Book Value Per Share	0.54	0.64	0.38	0.54
Tangible Book Value	44.87	46.14	25.54	36.27
Tangible Book Value Per Share	0.54	0.64	0.38	0.54

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q